Skip to content
Biodatica
Start free

Merck Sharp & Dohme LLC

Phoenix, Arizona

OncologyPhase IIIListed · MRK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Dec 9, 2025

    Bladder Cancer, Urinary Bladder Neoplasms · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

    ClinicalTrials.gov · NCT07222488 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Apr 8, 2024

    Bipolar I Disorder · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)

    ClinicalTrials.gov · NCT06273774 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Nov 14, 2023

    Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

    ClinicalTrials.gov · NCT06104449 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Oct 20, 2023

    Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

    ClinicalTrials.gov · NCT06041802 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Aug 8, 2023

    Hypercholesterolemia, Familial Hypercholesterolemia · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

    ClinicalTrials.gov · NCT05952869 (opens the source filing in a new tab)

  6. Trial

    PHASE2/PHASE3 registered

    May 31, 2023

    Heart Failure, Left Ventricular Systolic Dysfunction · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

    ClinicalTrials.gov · NCT05714085 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Jan 8, 2022

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

    ClinicalTrials.gov · NCT05144841 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Jun 9, 2017

    Renal Cell Carcinoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

    ClinicalTrials.gov · NCT03142334 (opens the source filing in a new tab)

  9. Trial

    PHASE2 registered

    Apr 15, 2009

    Lymphoma · COMPLETED · sponsor: Merck Sharp & Dohme LLC · Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

    ClinicalTrials.gov · NCT00875056 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources